- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05890794
Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
Open-Label Pilot Trial to Evaluate the Effects of Ilofotase Alfa on Biomarkers in Adult Patients With Hypophosphatasia
The goal of this clinical trial is to compare the effectiveness of two doses of ilofotase alfa, an enzyme replacement treatment, in patients with hypophosphatasia (HPP). The main question it aims to answer is if the harmful accumulating levels of extracellular inorganic pyrophosphate (PPi) and pyridoxal 5'-phosphate (PLP) can be reduced with ilofotase alfa.
Researchers will compare the two doses of ilofotase alfa to see if treatment effects differ between the doses.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recombinant human alkaline phosphatase (ilofotase alfa) is a full-length human chimeric alkaline phosphatase (ALP) that could benefit patients with hypophosphatasia (HPP), which is characterized by low activity of tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP).
This is a pilot trial for a potential future trial aimed at identifying whether treatment with ilofotase alfa can normalize circulating levels of PPi, PLP and other biochemical markers of TNSALP deficiency along with the safety/tolerability of different doses of ilofotase alfa. The trial is designed as a single-center, open-label, randomized, parallel group clinical trial in adult patients with HPP. Two different dose levels (0.8 mg/kg and 3.2 mg/kg) of ilofotase alfa will be assessed.
Participants will receive a single dose of ilofotase alfa, administered as a 1-hour intravenous infusion on Study Day 1. Participants will stay at the research center for a total of 12 days; from 2 days before study drug administration (run-in) to 10 days after treatment. An additional follow-up assessment is scheduled 14 days after administration of ilofotase alfa.
Blood and urine samples will be taken daily for drug concentration and laboratory measurements assessing safety and effectiveness of treatment. In addition physical examinations will be performed on Day 1 and as needed afterwards.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Kristie Bass
- Phone Number: +1-252-230-6338
- Email: k.bass@am-pharma.com
Study Locations
-
-
-
Würzburg, Germany, 97074
- Osteologie / Klinische Studieneinheit, Orthopädische Klinik - KLH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Genetically confirmed variant in the tissue-nonspecific isozyme alkaline phosphatase (ALPL)-Gene.
- Clinical symptoms of HPP.
- Medical history with 1) at least two independent measures of Alkaline Phosphatase (ALP) below lower level of normal (LLN) and 2) at least one measurement of either PPi or PLP above upper level of normal (ULN).
- Provision of signed and dated informed consent form (ICF) in accordance with local regulations at screening.
- Patients must agree not to get pregnant/not to get their partner pregnant, during the trial. Consequently, patients must agree to use adequate contraception as detailed in study protocol.
Exclusion Criteria:
- Participant is unable or unwilling to participate in all scheduled visits and perform all protocol-mandated assessments.
- Has a known or suspected hypersensitivity to ilofotase alfa or any components of the formulation used.
- Body weight < 40 kilogram and > 120 kilogram.
- Patient has a history of clinically significant abnormalities or of any illness that, in the opinion of the trial investigator, might confound the results of the trial or pose an additional risk to the patient by their participation in the trial.
- NSAID use in the past 2 weeks.
- Use of corticosteroids in the past 4 weeks.
- Use of compounds intended to interfere with bone metabolism (e.g. Denosumab, Teriparatide, Romosozumab, Raloxifene) in the past 3 months.
- Use of bisphosphonates in the past 2 years.
- Participation in a drug trial within 60 days, or five times the half-life of the drug, whichever is longer, prior to administration of ilofotase alfa.
- Use of asfotase alfa in the previous 3 months. Patients will not be withheld from approved asfotase alfa if medically indicated.
- A patient who is currently pregnant or lactating.
- Use of supplements including Vitamin B6.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 0.8 mg/kg ilofotase alfa
Single dose administered intravenously over 1 hour
|
Biological: single 1-hour intravenous infusion of 0.8 mg/kg ilofotase alfa
Other Names:
|
Experimental: 3.2 mg/kg ilofotase alfa
Single dose administered intravenously over 1 hour
|
Biological: single 1-hour intravenous infusion of 3.2 mg/kg ilofotase alfa
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in extracellular inorganic pyrophosphate (PPi)
Time Frame: Day 1 to Day 10
|
Mean (SD), median (minimum, maximum) change in PPi plasma concentrations over time, presented by dose group and overall
|
Day 1 to Day 10
|
Change in Pyridoxal 5'-phosphate (PLP)
Time Frame: Day 1 to Day 10
|
Mean (SD), median (minimum, maximum) change in PLP plasma concentrations over time presented by dose group and overall.
|
Day 1 to Day 10
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-emergent adverse events (TEAEs)
Time Frame: Day 1 to Day 15
|
Any untoward medical occurrence in a subject enrolled and treated in the clinical study regardless of its causal relationship to study drug.
|
Day 1 to Day 15
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr Seefried, Osteologie / Klinische Studieneinheit, Orthopädische Klinik - KLH, Würzburg, Germany
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AP-recAP-HPP-01-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypophosphatasia
-
AlexionEnrolling by invitationHypophosphatasia (HPP)France, Poland, United Kingdom, Germany, Spain, Saudi Arabia, United States, Canada, Russian Federation, Australia, Italy
-
Hvidovre University HospitalOdense University HospitalActive, not recruitingHypophosphatasia (HPP)Denmark
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Taiwan, United Kingdom, Australia, Canada, Germany, Spain
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, France, United Kingdom, Canada, Netherlands, Russian Federation, Turkey, Australia
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada, United Arab Emirates, United Kingdom
-
Alexion Pharmaceuticals, Inc.RecruitingHypophosphatasiaUnited States, Japan, Italy, Germany, Turkey, India, Australia, United Kingdom, Argentina, France, Canada
-
Alexion Pharmaceuticals, Inc.Not yet recruiting
Clinical Trials on Ilofotase Alfa, 0.8 mg/kg
-
AM-PharmaFGK Clinical Research GmbHRecruiting
-
AM-PharmaTerminatedAcute Kidney Injury Due to SepsisBelgium, Spain, United States, Austria, Denmark, France, United Kingdom, Finland, New Zealand, Australia, Germany, Canada, Netherlands, Ireland, Japan
-
Alexion PharmaceuticalsCompletedLysosomal Acid Lipase Deficiency | Cholesterol Ester Storage Disease(CESD) | LAL-DeficiencyFrance, United States, United Kingdom, Czechia
-
Zogenix International Limited, Inc., a subsidiary...CompletedDravet Syndrome | Lennox Gastaut SyndromeUnited States
-
Zogenix International Limited, Inc., a subsidiary...Active, not recruitingLennox Gastaut SyndromeUnited States, Australia, Belgium, Canada, Denmark, France, Germany, Italy, Japan, Mexico, Netherlands, Poland, Spain, Sweden
-
Yung Shin Pharm. Ind. Co., Ltd.TerminatedBreast Cancer | Hot FlashesTaiwan
-
AM-PharmaCompleted
-
Galderma R&DCompletedHealthy Subjects, Male or Female, of 18-60 Years Old, With Phototype I, II or III, Not Pre-treated/Pre-protected SkinFrance
-
Chiesi Farmaceutici S.p.A.ICON plcRecruiting
-
Auris Medical AGCompleted